Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 39,488 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

39,488 Papers indexed
1,440 Papers AI scored
39,488 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-10-21 09:15 AM
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

39488 results
B
Neurocognitive outcomes following postoperative paediatric cerebellar mutism syndrome: A systematic review.
PMID 40925717 Published: 2025-09-09 Ingested: 2026-08-02 12:05 AM Developmental medicine and child neurology
AI -
Standard 73.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.5/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 10.0; sample size: 80.0; recency: 100.0; abstract quality: 85.0.

B
History informing the future of exercise oncology.
PMID 40828163 Published: 2025-09-01 Ingested: 2026-08-02 12:05 AM Journal of the National Cancer Institute. Monographs
AI -
Standard 73.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.5/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 15.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Standard 73.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.5/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 20.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
Effectiveness of problem-solving skills training on the self-efficacy and self-concept of the adolescent with cancer.
PMID 40222310 Published: 2025-04-04 Ingested: 2026-08-02 12:03 AM Cancer treatment and research communications
AI -
Standard 73.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.5/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 20.0; sample size: 50.0; recency: 90.0; abstract quality: 85.0.

B
AI -
Standard 73.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.5/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 50.0; sample size: 70.0; recency: 90.0; abstract quality: 85.0.

B
[Analysis of non-communicable disease prevention and control policy implementation in China from 2014 to 2021].
PMID 40107783 Published: 2025-03-06 Ingested: 2026-08-02 12:04 AM Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
AI -
Standard 73.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.5/100. Study design: 75.0; human relevance: 90.0; therapeutic relevance: 40.0; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Standard 73.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.5/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 20.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

B
AI -
Standard 73.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.5/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 50.0; sample size: 70.0; recency: 90.0; abstract quality: 85.0.

Previous
Page 457 of 3291
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic